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of empiric antifungal therapy was assessed using univariate tech-
niques and multivariate logistic regression. RESULTS: A total of
81 patients were evaluated in this study. Forty-four percent
received broad spectrum, 46% received narrow spectrum, 
and 10% received no therapy. Overall mortality was 51%.
APACHEII >20 and narrow spectrum empiric therapy were inde-
pendent predictors of mortality (p = 0.011). Mortality rates were
similar in patients with Apache score >20 given broad (85%) or
narrow spectrum (79%) empiric therapy. However, in patients
with lower APACHEII scores (<20), mortality was signiﬁcantly
lower in patients started on broad spectrum (4%) compared to
narrow spectrum (46%). After excluding patients who died
while on therapy, average length of therapy was similar for both
groups (11–12 days). CONCLUSIONS: Patients with can-
didemia with an APACHEII score <20 treated with broad spec-
trum antibiotics had lower mortality rates compared to those
initially treated with narrow spectrum antifungal therapy.
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OBJECTIVE: Neutropenia following cancer chemotherapy is a
major risk factor for invasive fungal infections (IFIs). The high
rates of mortality associated with IFIs warrants the use of empir-
ical antifungal therapy. Conventional amphotericin B (CAB) is
considered to be the standard of care in persistently febrile 
neutropenic patients; however, infusion-related reactions and
nephrotoxicity limit its use. Although liposomal amphotericin B
(LAmB) has demonstrated similar efﬁcacy to CAB and is gener-
ally well tolerated, it is associated with a high acquisition cost.
Voriconazole is a potential alternative for empirical therapy of
IFIs. An algorithm for the management of febrile neutropenia
(FN) was implemented at the University of Michigan Health
System (UMHS). The new algorithm, implemented in January,
2003, recommends voriconazole as the preferred antifungal 
for adult Hematology/Oncology patients with FN, except those
with evidence of hepatic dysfunction or who are receiving gem-
tuzumab. The objective of this study was to determine the ﬁnan-
cial impact of this algorithm. METHODS: Patients on the adult
Hematology/Oncology service who ﬁrst received either LAmB or
voriconazole over a two-year period were identiﬁed retrospec-
tively using the UMHS Data Warehouse. Costs were evaluated
from the perspective of the Health System and compared
between the voriconazole and LAmB groups from ﬁrst the anti-
fungal dose to the time of hospital discharge. RESULTS: Seventy-
eight patients were included in the analysis (42LAmB and 36
voriconazole). Antifungal cost per patient declined from $4278
to $3331 in the voriconazole group. This represented a decrease
of $947 per patient. Laboratory cost per patient increased by
$579. The total cost per patient initiated on voriconazole
decreased by $1502. CONCLUSION: The implementation of an
algorithm incorporating voriconazole as the preferred antifungal
agent for empiric treatment of febrile neutropenia was associated
with decreased spending on antifungal agents, increased labora-
tory costs, and a decrease in total costs.
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OBJECTIVES: Children vaccinated with Prevenar have been
shown to be at reduced risk of meningitis, bacteraemia, pneu-
monia and acute otitis media. Vaccination may also affect risk
in unvaccinated individuals by reducing the circulation of infec-
tious organisms in the community, a phenomenon known as herd
immunity. This analysis examined the economic consequences of
Prevenar vaccination incorporating herd immunity effects.
METHODS: An existing model was adapted to consider herd
immunity effects in Germany. Vaccine coverage of 83% was
assumed and the model estimated the number of pneumococcal
events, deaths and associated costs in vaccinated individuals over
ten years. Efﬁcacy came from a large randomised study in the
US, corrected for age speciﬁc German epidemiology. Changes in
rates of infection with vaccine susceptible organisms have been
found by the Active Bacterial Core Surveillance Network in the
US, where Prevenar has been in use for several years. Costs were
estimated from the perspective of society, including four vaccine
doses, treating pneumococcal disease in hospital and the com-
munity, long term disability resulting from infections and 
social security payments. Future costs were discounted at 5%.
RESULTS: The model estimated that vaccination would avoid
98 cases of meningitis, 376 cases of septicaemia and 19 deaths
in vaccinated individuals. Using the percentage reduction in
disease observed in the USA, the model estimated that a further
3940 deaths would be avoided annually in unvaccinated indi-
viduals, mostly by reducing the incidence of pneumonia in the
elderly. The cost per life year gained was 43,000€ in the vacci-
nated cohort alone, but vaccination was cost saving when herd
immunity effects were incorporated. Findings are sensitive to
disease incidence, long-term costs of meningitis and vaccine cost.
CONCLUSION: The model showed that the beneﬁts of Preve-
nar extend beyond vaccinated individuals. Failing to consider
herd immunity effects may substantially understate the economic
beneﬁts of vaccination.
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OBJECTIVES: Acellular pertussis vaccines make immunization
of adolescents more feasible and may help reduce the burden of
pertussis. Based on recent estimates indicating that infection may
be much more common than previously thought, we updated an
economic evaluation of adolescent pertussis vaccination to assess
programs in this new context. METHODS: A model was previ-
ously developed to estimate the effects of pertussis vaccination
of adolescents (ages 11–18) including herd immunity. Inputs for
the US were taken from literature, government data and cost
databases. Recently published incidence estimates replaced pre-
vious CDC-based ones. Where adequate data were unavailable,
estimates were agreed to by an expert panel (the Global Pertus-
sis Initiative). Health beneﬁts were quantiﬁed as cases, deaths,
and disability avoided, and life years gained. Both direct medical
costs and lost productivity costs were considered. All outcomes
were discounted at 3% per year. Time horizon was ten years.
Extensive uni- and multivariate sensitivity analyses were com-
pleted. RESULTS: Adopting new incidence estimates dramati-
cally improves the value of adolescent vaccination, with cases
avoided exceeding two million over ten years. The economic
results switch from the original cost-effective situation to direct
medical savings of $719 million and societal of $1.2 billion, if
parameters other than incidence are unchanged. Sensitivity
analyses show that the cost per case would need to be < 10% of
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the base case for savings to be eliminated, and that even without
herd immunity, vaccination would lead to signiﬁcant savings.
With herd immunity of 20%, vaccination remains cost-saving
even if its cost exceeds $100 per immunization and, without herd
immunity, up to a cost of $34. CONCLUSIONS: Based on recent
estimates of pertussis incidence and assuming that the conse-
quences of these previously unreported cases are similar to those
of cases described in the literature, vaccinating adolescents
against pertussis appears an attractive strategy.
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OBJECTIVES: In immunocompromised patients, presumed sys-
temic fungal infections (PSFI) are treated empirically with an
intravenous antifungal to reduce the occurrence of documented
infections and associated mortality. In the Korean health care
setting, conventional amphotericin B (CAB) is currently the
single ﬁrst line treatment choice. However, its toxicity often
results in discontinuation or suboptimal dosing. Liposomal or
lipid formulations of amphotericin B, with improved toxicity
proﬁle, remain restricted for second line use due to their high
acquisition cost. The objective was to compare the cost-
effectiveness of intravenous itraconazole (IVitra) with CAB as
ﬁrst line empirical treatment of presumed SFI in neutropenic
cancer and bone marrow transplant (BMT) patients.
METHODS: A medical decision tree was developed, including
probabilities of toxicity, response, pathogen documentation and
second line treatments. Clinical data were obtained from ran-
domized trials comparing IVitra with CAB (n = 392) and CAB
with LAB (n = 687). Resource use was obtained from a panel of
clinical experts, unit costs from ofﬁcial sources (public payer per-
spective). Cost-effectiveness was expressed as cost per additional
responder (deﬁned as patient without fever or major toxicity).
RESULTS: The total cost of PSFI per neutropenic cancer patient
was lower for IVitra ($7234) than for CAB ($8023). The same
cost ranking was obtained in BMT patients, however with higher
hospitalization costs. The variables accounting for cost differ-
ences were ﬁrst and second line antifungal drug costs and costs
of concomitant drugs. In cost-effectiveness analysis, IVitra was
dominant over CAB combining greater effectiveness (because of
less toxicity) and lower costs. The result was robust to wide vari-
ations in expert reported medical practice. CONCLUSION:
IVitra was shown to be a cost-effective and cost saving alterna-
tive to CAB for empirical treatment of presumed SFI in neu-
tropenic cancer and BMT patients. These conclusions are in line
with those obtained in different European countries, applying the
same methodology.
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OBJECTIVE: To assess the cost effectiveness of an immunisa-
tion programme for rotavirus-associated gastroenteritis among
children aged ﬁve years old and under in the UK. METHOD:
Economic evaluation based on a decision analytical model using
data from a review of published evidence was used. Incremental
cost effectiveness ratios are estimated from both the societal and
health sector perspectives. RESULTS: Using conservative vaccine
efﬁcacy estimates, current immunisation rates and a vaccine cost
of £60 per completed course, rotavirus immunisation would
incur a net health sector cost of £27.8 million per birth cohort
(£42.52 per child). A vaccination programme could, however,
provide net savings to society of £4.8 million; that is, from 
the societal perspective a programme of vaccinating against
rotavirus dominates the alternative of no programme by pre-
venting more cases and costing less. Threshold analysis identi-
ﬁed a breakeven price of £13.26 per course, such that any price
less than this would also result in cost savings for the health
sector. These results are, however, sensitive to a range of vari-
ables and, in particular, society’s cost savings are negated if
parents spend less time away from employment and/or forego
less income. CONCLUSIONS: It appears that some of the health
sector costs and all of the societal costs of gastroenteritis in chil-
dren can be avoided by an immunisation programme using 
one of the two vaccines recently developed. The net cost to the
health sector may, however, be considered worthwhile if there is
a sufﬁcient improvement in the quality-of-life of children and
parents affected by gastroenteritis; this study did not ﬁnd any
evidence of research which has measured the utility gains from
vaccination.
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OBJECTIVES: Meningococcal disease can have severe conse-
quences, and outbreaks require immediate outlay of resources.
Menactra, a new conjugate vaccine for meningococcal disease,
provides protection against serogroups A, C, Y and W-135. This
study examines the cost-effectiveness of routinely vaccinating
adolescents in the US with Menactra. METHODS: The eco-
nomic implications of meningococcal disease vaccination in the
US were assessed using a discrete event simulation. These analy-
ses compare routine vaccination of 12-year-olds with Menactra
to no routine vaccination. Both the direct beneﬁts of vaccination
and the indirect ones resulting from herd immunity are modeled.
The impact of vaccination on outbreaks of disease is also
modeled. Outcomes include cases, deaths, sequelae, life years
lost, quality adjusted life years (QALYs) lost and both direct and
indirect costs (2003 USD). In the base case, the vaccine price was
$70. Vaccine efﬁcacy was assumed to be 90% over 10 years. All
outcomes are discounted at 3% per annum. RESULTS: Without
vaccination, there is an average of 2808 cases per year and 375
deaths. A total of 2.9 community-based and 6.1 school-based
outbreaks per year are predicted. The cost of meningococcal
disease averages $311 million per year. Routine vaccination
reduces the number of cases to under 2000, deaths to 230, com-
munity outbreaks to 0.7 and school-based outbreaks to 1.7.
Disease costs are reduced by over $100 million, but vaccination
increases total costs, resulting in a cost per discounted QALY
gained of $36,868. Sensitivity analyses reveal that outcomes are
strongly inﬂuenced by the duration of protection conferred on
those vaccinated, and the extent of herd immunity resulting from
routine immunization. CONCLUSION: Vaccinating adolescents
in the US with Menactra will reduce burden of disease and can
be cost-effective. Outcomes should be reevaluated as more data
become available.
